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A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efﬁcacy of F16-IL2, a
recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumors (phase Ib)
and metastatic breast cancer (phase II). Six patient cohorts with progressive solid tumors (n D 19) received escalating
doses of F16-IL2 [5–25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of
doxorubicin (0–25 mg/m2) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n D
10) received the drug combination at the RD. Clinical data and laboratory ﬁndings were analyzed for safety, tolerability,
and activity. F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25 mg/m2). No
human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent
over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively.
Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67%
disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks),
considering 14 and 9 patients evaluable for efﬁcacy. One patient experienced a long lasting partial response (45 weeks),
still on-going at exit of study. F16-IL2 can be safely and repeatedly administered at the RD of 25 MIU in combination
with 25 mg/m2 doxorubicin; its safety and activity are currently being investigated in combination with other
chemotherapeutics, in order to establish optimal therapy settings.
Introduction
Interleukin-2 (IL2) is a proinflammatory cytokine, which is
normally produced during an immune response, activating
helper T-cells, cytotoxic T-cells, B-cells, natural killer (NK)
cells, and macrophages.1 Human recombinant IL2 (Proleukin,
Novartis) is approved by US Food and Drug Administration
(FDA) for the treatment of metastatic renal cell cancer,2 and
metastatic melanoma.3 However, IL2 treatment is limited by its
own toxicity profile; the most frequently reported side effects
include capillary leak syndrome, resulting in hypotension, renal
dysfunction with oliguria/anuria, pulmonary congestion, and
mental status changes.2 These severe adverse events warrant a
thorough clinical evaluation and the administration of human
recombinant IL2 in a hospital setting under adequate medical
supervision.
Cytokines do not preferentially localize to the tumor site after
intravenous administration, resulting in serious side effects in
vivo, which prevent dose escalation to the concentrations that are
needed to achieve curative anti-tumor effects. A way to control
the systemic side effects of cytokine administration is driving the
cytokines to the tumor site by the antibody-mediated targeted
delivery.4-6 With such approach, antibodies are used as modular
components for the preparation of fusion proteins
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(“immunocytokines”), which allow the selective localization of
the cytokine payload on neoplastic masses.
F16-IL2 is a noncovalent homodimeric recombinant fusion
protein consisting of a human antibody fragment specific to the
A1 domain of tenascin-C in the single chain fragment variable
(scFV) format, named F16, and of the human cytokine IL2.
Tenascin-C is a glycoprotein of the extracellular matrix. It com-
prises several fibronectin type 3 homology repeats that can be
either included or omitted in the primary transcript by alternative
splicing, leading to small and large isoforms that have distinct
biological functions (Fig. 1).7,8 Whereas the small isoform is
expressed in several tissues, the large isoform of tenascin-C exhib-
its a restricted pattern of expression. It is virtually undetectable in
healthy adult tissues but is expressed during embryogenesis and is
re-expressed in adult tissues undergoing tissue remodeling,
including neoplasia. Its expression is localized around vascular
structures in the tumor stroma of a variety of different tumors,
including breast carcinoma,7 oral squamous cell carcinoma,9
lung cancer,10 prostatic adenocarcinoma,11 colorectal cancer,12
or astrocytoma and other brain tumors.13,14 Using MDA-MB-
231xenograft model of human breast cancer, F16-IL2 has been
shown to selectively deliver IL2 to the cancer sites by localizing
to tumor tissues.15
The clinical development of F16-IL2 was supported by pre-
clinical studies performed in mice and toxicology studies com-
pleted in cynomolgus monkeys, which indicated that F16-IL2 is
able to substantially increase the therapeutic efficacy of com-
bined chemotherapy, and that did not raise any safety
concerns.15
This is the first clinical study of F16-IL2 in combination
with doxorubicin conducted in cancer patients. Doxorubicin
is a well-characterized chemotherapeutic agent, which has
been commonly used in the treatment of a wide range of
cancers, including hematological malignancies, many types of
carcinoma and soft tissue sarcomas.16 Because of known
activity of F16-IL2 in preclinical models of breast cancer,15
and due to confirmed expression of the large isoform of
Tenascin-C in this tumor type,17 breast cancer patients were
included in the phase II part of the study, after definition of
the dose in solid cancer patients. Moreover, additional clini-
cal experimental evidence of the ability of the F16 antibody
to selectively target breast cancer was provided by a radio-
immunotherapeutic clinical study in patients with cancer
(Supplementary Fig. 1).
Results
Patients’ characteristics
Nineteen patients with progressive
solid tumors were enrolled in the phase
Ib part of the study (Table 1) and
treated with increasing doses of F16-
IL2 (Fig. 2A). All patients were evalu-
able for safety, and 14 for anticancer
activity.
Ten patients with metastatic breast
cancer were enrolled in the phase II part of the study (Table 1)
and treated with 25 MIU of F16-IL2 in combination with
25 mg/m2 of doxorubicin (Fig. 2A).
All patients were evaluable for safety, and 9 for anticancer
activity. Two out of 3 breast cancer patients for phase I and 3 out
of 10 patients for phase II were treated in the past with adjuvant
anthracycline-based chemotherapy. A detailed list of patient
demography data and characteristics, including cancer diagnosis
and prior therapies, is given in Table 1.
Dose finding and safety
The safety study population includes all 29 patients who
received at least one drug administration of F16IL2 (26 patients
received at least one administration of doxorubicin). Four
patients were recruited at the second dose level, as one discontin-
ued treatment before completion of cycle 1 for an early progres-
sion. No F16-IL2 dose reduction was reported, while 11 patients
overall (7/26 patients allocated to 25 mg/m2 doxorubicin: 4/16
for Phase I and 3/10 for Phase II) were treated with at least one
reduced dosage of doxorubicin (i.e., inferior to 75% of the origi-
nal dose, according to protocol), and one patient (1/26) received
80% of the originally administered doxorubicin dose, according
to the investigator’s judgment.
The complete list of treatment-related adverse events is
depicted in Table 2; the most frequent adverse events included
asthenia, pyrexia, and constipation.
No dose-limiting toxicity (DLT) was observed in this trial and
no expansion of the dose cohorts was needed to further explore
the safety of the drug combination.
In a 76-year-old female patient with pancreatic cancer
enrolled in the 4th cohort, grade 3 (G3) febrile neutropenia was
observed; the patient later recovered and stopped the treatment;
such event was assessed as serious and expected.
No case was considered a serious, unexpected suspected
adverse event (SUSAR) and no deaths related to the combination
therapy were reported during the study.
Pharmacokinetic and HAFA
Figure 3 shows the mean concentrations (and standard devia-
tions) of F16-IL2 by dose group, during week 1 and week 2 of
the first cycle of treatment. The maximum concentration (Cmax)
of F16-IL2 increased dose-proportionally during week 1 but not
during week 2. Cmax occurred almost within 1 hour from the
start of the intravenous infusion. Table 3 shows Cmax and
Figure 1. Domain structure of Tenascin- C
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half-life time per groups of dose assuming a non-compartmental
approach. After reaching Cmax, the F16-IL2 concentration
decreased with a terminal half-life of ca. 13 hours for cohorts
dosed at lower levels and ca. 8 hours for cohorts dosed at higher
levels.
Immunogenic response against F16-IL2 induced after treat-
ment of patients was investigated using ELISA methodology and
Surface Plasmon Resonance (SPR), on BiacoreT100. A total of
46 serum samples from 19 patients treated repeatedly with F16-
IL2 were tested for the presence of HAFA specific to F16-IL2.
All analyzed samples in the sandwich ELISA resulted negative.
SPR detected in one patient a positive result for the end of treat-
ment sample, with a very low signal correlated to presence of IgG
antibodies, the subsequent time point at the follow up visit was
negative.
Activity
Response was measured at week 8 after completion of 6
administrations of both F16-IL2 and doxorubicin. Patients with
stable or responding disease received combination therapy for up
to 6 months.
Patients with clinical diagnosis of progressive disease (PD)
(e.g., symptomatic deterioration without proof of progressive dis-
ease) were withdrawn from the study treatment. Patients
Figure 2. Study design and treatment schedule (A) Study design (B) Treatment schedule. Patients were screened up to 14 d prior to beginning of study.
Each cycle of treatment comprises F16-IL2 administration on days 1, 8 and 15 (indicated as black arrows), and doxorubicin administrations on the same
days (indicated as gray arrows), followed by 13 d rest (total duration of one cycle is 28 d). Patients could receive up to 6 treatment cycles. The tumor
assessments (indicated by dotted lines) were performed according to RECIST: the lesions were measured at screening and at the end of cycle 2, 4 and 6.
Table 1. Patients’ demographics
Characteristics Phase I (n) Phase II (n)
Number of enrolled patients 19 10
Median (and range) age at study entry (years) 63 (32–75) 58 (40–77)
Male/Female 9/10 0/10
ECOG PS at baseline0/1 11/8 5/4
Cancer diagnosis
Breast cancer 3 10
Colorectal cancer 2
Endometrial cancer 2
Pancreas cancer 2
Prostate cancer 2
Malignant vascular tumor 2
Cancer of tongue 1
Choroidal melanoma 1
Pleural cancer 1
Tyhmoma 1
Thyroid cancer 1
Cervix uteri cancer 1
Prior Therapy
Surgery 14 9
Chemotherapy 17a 10b
Radiotherapy 9 8
Median number of prior chemotherapy regimens.
a2 (range 1–12).
b3 (range 1–7).
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evaluated as PD at the first tumor assessment but still considered
in good clinical condition continued treatment for 2 additional
cycles at the Investigator’s discretion.
Two out of 29 enrolled patients were replaced; one patient of
the 2nd cohort had an early disease progression, and one patient
enrolled during the phase II part of the study had a septic shock,
possibly related to doxorubicin; both patients discontinued the
treatment before completion of cycle 1 and could therefore be
replaced, according to protocol. Three more patients discontin-
ued the treatment after completion of cycle 1 but before reaching
the first tumor assessment time point (i.e., end of cycle 2), and
therefore could not be evaluated for activity.
After 2 cycles of treatment, the disease control rate was
about 57% considering 14 evaluable patients during the
phase Ib (14 patients with tumor assessment 8 weeks post
baseline, 15 patients with at least one tumor assessment avail-
able post baseline), and about 67% considering 9 evaluable
patients during the phase II part of the study. The disease
control rates decreased to 43% and 33% after 12 weeks,
respectively for Phase I and II. Among these latter 6 patients
of phase II, one further improved into a long lasting partial
response (up to 312 days). No complete response (CR) and
partial response (PR) were observed in Phase Ib; 2/3 patient
showed stable disease (SD) in the first cohort 5 MIU F16-
IL2, 2/3 in the cohort 5 MIU F16-IL2 and 20 mg/m2 Doxo-
rubicin, 1/2 in the cohort 5 MIU F16-IL2 and 25 mg/m2
Doxorubicin, 2/2 in the cohort 10 MIU F16-IL2 and
25 mg/m2 Doxorubicin, 0/2 in the cohort 15 MIU F16-IL2
and 25 mg/m2 Doxorubicin and 1/2 in the cohort 25 MIU
F16-IL2 and 25 mg/m2 Doxorubicin.
In the phase Ib patients, median progression free survival
(PFS) was 110 d [based on 15 patients with at least one tumor
assessment post baseline, censored n D 1 (patient with SD in
the last assessment after 193 d); 95% confidence interval (CI)
76–287 d]; while in the phase II patients, median PFS was
125 d [based on 9 patients, censored n D 4 (3 patients with
SD and 1 patient with PR at the last assessment); 95% CI 54-
upper limit not evaluable; first quartile 80 d, third quartile
206 d].
Median overall survival (OS) was 293 d [based on 18 patients,
censored n D 4; 95% CI 144 – 646 d] and 351 d [based on 9
patients, censored n D 4; 95% CI 58 – upper limit not evalu-
able], for patients enrolled in the phase Ib and in the phase II
part of the study, respectively.
Table 2. Incidence of adverse events (AEs)
Patients with related adverse events grade <3 and 3 by dose level
5 MIU
(n D 3)
5 MIU
20 mg/m2
doxo (n D 4)
5 MIU
25 mg/m2
doxo (n D 3)
10 MIU
25 mg/m2
doxo (n D 3)
15 MIU
25 mg/m2
doxo (n D 3)
25 MIU
25 mg/m2
doxo (n D 13)
Any Dose
(n D 29)
Related AEs by system organ class G<3 G3 G<3 G3 G<3 G3 G<3 G3 G<3 G3 G<3 G3 All Grade
Blood and lymphatic system disorders 1 1 1 1 10 7 14
Cardiac disorders 1 1 2
Eye disorders 1 1
Gastrointestinal disorders 1 2 2 1 9 1 15
General disorders and administration
site conditions
2 2 1 1 1 2 10 3 19
Investigations 1 1 2
Metabolism and nutrition disorders 1 1 2 2 4
Muscoskeletal and connective tissue
disorders
1 1
Nervous system disorders 1 1
Renal and urinary disorders 1 1
Reproductive system and breast
disorders
1 1
Respiratory, thoracic and mediastinal
disorders
1 1 2
Skin and subcutaneous tissue disorders 2 3 5
Vascular disorders 1 1 2
The toxicities were graded according to Common Terminology Criteria for Adverse Events v 3.0. The System Organ Class was coded using the Medical Dic-
tionary for Regulatory Activities. Blood and lymphatic system disorders include anaemia, neutropenia, and leucopenia; cardiac disorders include pericardial
effusion and tachycardia; eye disorders include conjunctivitis; gastrointestinal disorders include constipation, vomiting, nausea, abdominal pain, stomatitis,
gastritis, and oesophagitis; general disorders and administration site conditions include asthenia, pyrexia, fatigue, ﬂu-like syndrome, and mucosal inﬂamma-
tion; investigations include weight decrease and increase of alanine aminotransferase, aspartate aminotransferase; metabolism and nutrition disorders include
anorexia and hypokalaemia; muscoloskeletal and connective tissue disorders include arthralgia; nervous system disorders include headache; renal and urinary
disorders include hyperazotemia; reproductive system and breast disorders include pelvic pain; respiratory, thoracic and mediastinal disorders include dys-
pnoea, sinusitis; skin and subcutaneous tissue disorders include alopecia, palmar-plantar erythrodysaestesia syndrome, and nail disorders; vascular disorders
include hypertension and phlebitis.
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A waterfall plot indicating the best
response for target lesions compared
with baseline experienced by evaluable
patients according to the clinical cen-
ters’ assessment is shown in Figure 4A.
The plot reports the maximum percent-
age of shrinkage of target lesions
according to Response Evaluation Cri-
teria In Solid Tumors (RECIST),18 by
F16-IL2 dose group (i.e., cohort 1 to 3
received 5 MIU; cohort 4 received 10
MIU; cohort 5 received 15 MIU;
cohort 6 and phase II patients received
25 MIU). Selected examples of target
lesion shrinkages are shown in
Figure 4B and C; panel 4B reports the
partial response of a breast cancer
patient (No. 21), whose target lesion
diameters reduced up to -59%, and whose response lasted (45
weeks) until patient began a new anticancer treatment. Panel 4C
displays a hilar lymph node, a precarinal lymph node, and several
liver lesions of a breast cancer patients (No. 23), which were kept
stable (¡11%) by the F16-IL2/doxorubicin combination for up
to 19 weeks, until she withdrew from the study for progression of
bone metastasis and beginning of radiotherapy.
Discussion
This is the ‘first-in-man’ study of the immunocytokine F16-
IL2 combined with doxorubicin. The results of this phase Ib/II
trial demonstrate that F16-IL2 can be safely administered at 25
MIU IL2 equivalents in combination with the RD of doxorubi-
cin to patients with progressive solid tumors. The combination
treatment was well tolerated and all reported toxicities were man-
ageable and resolved completely. None of the 19 patients
enrolled during phase Ib into the 6 planned cohorts experienced
a DLT; this led to the administration, during the phase II part of
the study, of the maximum administered dose (MAD; i.e., 25
MIU), without having formally defined the maximum tolerated
dose (MTD).
The maximum dose of F16-IL2 to be administered in this
trial was defined exploiting the analogy of this drug with the
immunocytokine L19-IL2, which is composed of an antibody
fragment specific to the tumor marker EDB domain of fibronec-
tin and of human IL2.19,20 However, the comparison of the PK
analysis of F16-IL2, presented in this trial, with the PK data col-
lected in previous trials run with L19-IL2,19,20 highlighted few
discrepancies between the 2 drugs, which could not be predicted
on the basis of preclinical data, and which may lead to remark-
able differences in the dose definition. Specifically, the Cmax val-
ues registered after infusion with the MAD of the 2
immunocytokines (i.e., 25 MIU IL2 equivalents for F16-IL2 and
22.5 MIU IL2 equivalents for L19-IL2) differ by a factor of
approximately 10 (i.e., 100–120 ng/ml and 800–1200 ng/ml,
for F16-IL2 and L19-IL2, respectively) indicating that the
optimal effective dose of F16-IL2 might be significantly higher
than the defined RD of L19-IL2.
In light of these safety and PK findings, this trial was prema-
turely stopped after the enrolment of 10 patients in the phase II
part of the study (the original design foresaw the enrolment of 20
patient in the phase II), in order to refine the clinical develop-
ment plan and in order to avoid treating patients with subopti-
mal F16-IL2 dosages.
Nevertheless, F16-IL2 has shown some preliminary signs of
anti-cancer activity, when given in combination with doxorubicin,
which may develop into even more striking effects once the opti-
mal drug dosage is defined. Moreover, a similar trial which is cur-
rently ongoing, during which F16-IL2 is given in combination
with paclitaxel to patients with solid tumors, is confirming the
safety of the immunocytokine/chemotherapy combination and is
showing even more pronounced benefits to the cancer patients in
terms of both disease stabilization and tumor shrinkage.
In conclusion, the data presented here lay the foundation for
further exploring the safety and activity of F16-IL2 and for future
clinical trials with F16-IL2 in combination with approved anti-
tumor drugs.
Table 3. Cmax and T1/2 distribution by groups of dose
Cmax (ng/mL) T1/2(hour)
Dose MIU) Nr. Week Min. Median Max. Min. Median Max.
5 10 1 7.52 22.04 35.56 3.91 13.93 23.15
10 2 9.32 16.67 46.60 3.40 13.36 24.33
10 3 1 51.69 63.95 70.61 10.07 11.86 16.55
3 2 29.14 49.70 84.64 13.11 16.01 17.30
15 3 1 56.64 78.52 100.05 8.93 11.06 11.36
3a 2 39.62 58.02 103.81 8.86 11.35 13.84
25 8 1 24.53 86.93 404.41 6.30 8.83 25.85
6 2 55.69 104.29 125.55 6.29 7.40 9.95
Cmax and T1/2 minimum, maximum and median data by groups of dose and
week of sampling. The T1/2 was calculated following a non-compartmental
approach.
aThe T1/2 was calculated on a population of only 2 patients.
Figure 3. Pharmacokinetic analysis. Mean concentrations C standard deviation of F16-IL2 following
administration of doxorubicin 25 mg/m2 and increasing doses of F16-IL2 (i.e., ^ D 5 MIU,  D 10
MIU & D 15 MIU & D 25 MIU) are plotted versus time, by dose group; the dose is expressed in IL2
equivalents. Data were collected on day 1, corresponding to ﬁrst F16-IL2 dose (A), and on day 8, corre-
sponding to the administration of the second F16-IL2 dose (B), during the ﬁrst cycle of treatment.
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Materials and Methods
Study design and objectives
The trial here described was an open-label, non-randomized,
phase I/II study, involving 4 Italian hospitals. During the dose
escalation phase Ib part of the study, 3 to 6 patients were enrolled
in sequential cohorts, corresponding to escalating doses of F16-
IL2 (from 5 to 25 MIU of IL2 equiva-
lent), in combination with escalating
doses of doxorubicin (Ebewe Italia S.r.
l., Rome, Italy; from 0 to 25 mg/m2).
Escalation schemes and treatment schedules are described in
Figure 1A and B, respectively.
Clinical-grade F16-IL2 was provided by Philogen S.p.A.
(Siena, Italy;15), as a liquid, sterile, apyrogenous preparation.
The primary objective of phase Ib part of the study was to deter-
mine the RD of F16-IL2 in combination with doxorubicin, in
patients with advanced solid tumors, while the secondary
Figure 4. Waterfall Plot and radiological
documentation of responses. (A) Best
responses (deﬁned as the largest shrink-
age in the sum of diameters of target
lesions at any moment in time, compared
to baseline) of evaluable patients treated
with the F16-IL2/doxorubicin combination
are reported in plot. Patients 1–3 received
5 MIU IL2 equivalents of F16-IL2; patients
4–6 received 5 MIU of F16-IL2 plus
20 mg/m2 of doxorubicin; patients 7–9
received 5 MIU of F16-IL2 plus 25 mg/m2
of doxorubicin; patients 10–12 received
10 MIU of F16-IL2 plus 25 mg/m2 of doxo-
rubicin; patients 13–15 received 15 MIU of
F16-IL2 plus 25 mg/m2 of doxorubicin;
patients 16–27 received 25 MIU of F16-IL2
plus 25 mg/m2 of doxorubicin. Patients
No. 4, 12, 15, 18, and 24 are not reported
in the graph since they were not evalu-
ated for tumor response at any tumor
assessment time point after baseline.
Patient No. 4 discontinued treatment dur-
ing cycle 1 due to worsening clinical con-
ditions. He was replaced by Patient No.
904; Patient No. 12 withdrew from the
study after cycle 1 for worsening of clini-
cal condition; Patient No. 15 was assessed
as progressive during cycle 1; Patient No.
18 discontinued treatment during the ﬁrst
2 cycles due to severe adverse event (rec-
tal hemorrhage); Patient No. 24 discontin-
ued treatment after the second dose due
to an adverse event and was replaced by
Patient No. 924. Asterisks mark patients
whose tumor shrinkage was accompanied
by the development of new lesions, so
that they were classiﬁed as PD. Computer-
ized Tomography scan documentation of
selected patients treated with the F16-
IL2/doxorubicin combination are shown
in (B and C). (B) CT images of a liver lesion
(I), and 2 enlarged lymph nodes (II & III),
indicated by the green arrows, of patient
No. 21 (best response -59%) are shown.
(C) CT images of the right hilar lymph
node (I), a precarinal lymph node (II), and
several liver lesions (III), of patient No. 23
(best response ¡11%), are shown. CT
images were taken at baseline and at the
following time-points indicated in ﬁgure.
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objectives included the investigation of the pharmacokinetic
properties of F16-IL2, the analysis of human anti-fusion protein
antibodies HAFA levels, and the study of early signs of anti-
tumor activity of the investigational drug combination. For phase
II part of the study, the primary objective was to investigate the
anti-cancer activity of the drug combination as measured by con-
firmed objective response rate (ORR), while secondary objectives
included the investigation of safety and tolerability, analysis of
HAFA levels, and assessment of PFS, defined as the time from
enrolment until objective tumor progression or death and
median overall survival (mOS) defined as the time, calculated
from enrolment until death, when 50% of the patients are dead.
During the phase Ib part of the study, the highest investigated
dose level for which a DLT incidence was observed in not more
than one out of 6 patients, was defined as RD. DLT was defined
using Common Terminology Criteria for Adverse Events v3.0
(CTCAE),21 as described in the supplementary materials.
Study population and eligibility criteria
Inclusion and Exclusion Criteria are summarized in the sup-
plementary materials. Briefly, solid cancer patients amenable for
doxorubicin treatment were eligible for phase Ib (except cohort
1, where patients could not be amenable for doxorubicin treat-
ment), whereas only breast cancer patients were recruited for the
phase II part of the study. All enrolled patients (or their legally
acceptable representatives, when applicable) signed an informed
consent form before being admitted into the study. The study
was conducted in accordance with the Declaration of Helsinki,
and was approved by the Italian national competent authority
and the hospitals’ ethic committees. The trial is registered in
http://clinicaltrials.gov/ with the code NCT01131364.
Safety and efficacy assessments
At screening, demographic data and complete medical and
surgical history were collected; moreover, ECG, Multi Gated
Acquisition (MUGA) scan, assessment of baseline findings
(according to Medical Dictionary for Regulatory Activities v10),
assessment of concomitant medications, complete physical exam-
ination and vital signs, blood sampling for standard safety labora-
tory examination, thyroid function and HAFA, urine sampling,
as well as disease assessment according to RECIST criteria18 were
performed.
During the study, adverse events and toxicity were graded as
per CTCAE;21 disease status was assessed every 2 cycles (corre-
sponding to 6 F16-IL2 infusions and 8 weeks) and at study dis-
continuation according to RECIST criteria.18
All patients with at least one drug intake were analyzed for
safety evaluation. Patients who discontinued prior to having an
assessment at week 8 were considered non-responders for the effi-
cacy evaluation.
Each patient returned for an end-of-treatment visit when dis-
ease was assessed as progressive, after discontinuation of treat-
ment or at week 24 (last week of treatment). The follow-up visits
were performed starting approximately 5 weeks from last admin-
istration of the study drug, and every 8 weeks until disease pro-
gression, beginning of another anti-cancer therapy, or
completion of 12 months.
The final analysis for PFS and OS was conducted when all
patients had experienced the event of interest or had been fol-
lowed for at least 12 months after enrolment.
Pharmacokinetics and HAFA
For pharmacokinetics (PK) analyses, venous blood samples
(6 ml) were collected repeatedly from all phase I study patients
and 5 phase II patients during week 1 and week 2 of cycle 1.
Serum was frozen and stored at -80C until analyzed. F16-IL2
serum concentration was assessed using a validated method: a
ligand-binding assay where the antigen tenascin C A1 domain
was captured onto ELISA plates, and the analyte (F16-IL2)
bound to immobilized antigen was detected by a mouse anti-
human IL2 antibody and a goat anti-mouse IgG peroxidase
conjugate.
The immunogenic potential of F16-IL2 was monitored by the
analysis of HAFA formation. Serum samples for HAFA analysis
were collected from all patients before F16-IL2 administration
on day one, at day 56, at the end of study drug treatment and at
the end of follow-up period. The immunogenicity of F16-IL2
was evaluated at Philogen S.p.A., Siena, Italy, using a validated
ELISA method and orthogonal technology on SPR using a
BiacoreT100 instrument.
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